Evidence map›Paper›PMID 38162617›Full record

ArticleFrontiers in public health2023

Ciprofloxacin and pegylated G-CSF combined therapy mitigates brain hemorrhage and mortality induced by ionizing irradiation.

Juliann G Kiang, Georgetta Cannon, Matthew G Olson, Min Zhai, Akeylah K Woods, Feng Xu, Bin Lin, Xianghong Li, Lisa Hull, Suping Jiang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Juliann G KiangRadiation Combined Injury Program, Department of Scientific Research, Armed Forces Radiobiology Research Institute, Bethesda, MD, United States.
Georgetta CannonRadiation Combined Injury Program, Department of Scientific Research, Armed Forces Radiobiology Research Institute, Bethesda, MD, United States.
Matthew G OlsonRadiation Combined Injury Program, Department of Scientific Research, Armed Forces Radiobiology Research Institute, Bethesda, MD, United States.
Min ZhaiRadiation Combined Injury Program, Department of Scientific Research, Armed Forces Radiobiology Research Institute, Bethesda, MD, United States.
Akeylah K WoodsRadiation Combined Injury Program, Department of Scientific Research, Armed Forces Radiobiology Research Institute, Bethesda, MD, United States.
Feng XuRadiation Combined Injury Program, Department of Scientific Research, Armed Forces Radiobiology Research Institute, Bethesda, MD, United States.
Bin LinRadiation Combined Injury Program, Department of Scientific Research, Armed Forces Radiobiology Research Institute, Bethesda, MD, United States.
Xianghong LiRadiation Combined Injury Program, Department of Scientific Research, Armed Forces Radiobiology Research Institute, Bethesda, MD, United States.
Lisa HullRadiation Combined Injury Program, Department of Scientific Research, Armed Forces Radiobiology Research Institute, Bethesda, MD, United States.
Suping JiangRadiation Combined Injury Program, Department of Scientific Research, Armed Forces Radiobiology Research Institute, Bethesda, MD, United States.
Mang XiaoRadiation Combined Injury Program, Department of Scientific Research, Armed Forces Radiobiology Research Institute, Bethesda, MD, United States.
Armed Forces Institute of Pathology · US

Funding

Ciprofloxacin enhances DNA repair capacity after radiation combined injuryR33AI080553 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI KIANG, JULIANN GONG · 2010 to 2012
$1.1M
Ciprofloxacin enhances DNA repair capacity after radiation combined injuryR21AI080553 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI KIANG, JULIANN GONG · 2008 to 2009
$378k
NIAID NIH HHS R21 AI080553NIAID NIH HHS R33 AI080553NIAID NIH HHS Y01 AI005045
6 · The paper itself

Abstract

Introduction: Brain hemorrhage was found between 13 and 16 days after acute whole-body 9.5 Gy Methods: B6D2F1 female mice were exposed to Results: CIP + PEG enhanced survival after IR by 85% vs. the 30% improvement by PEG alone. IR depleted platelets, which was mitigated by PEG or CIP + PEG. Brain hemorrhage, both surface and intracranial, was observed, whereas the sham mice displayed no hemorrhage. CIP or CIP + PEG significantly mitigated brain hemorrhage. IR reduced GFAP levels that were recovered by CIP or CIP + PEG, but not by PEG alone. IR increased IL-18 levels on day 4 only, which was inhibited by CIP alone, PEG alone, or PEG + CIP. IR increased C3 on day 4 and day 15 and that coincided with the occurrence of brain hemorrhage on day 15. IR increased phosphorylated p53 and p53 levels, which was mitigated by CIP, PEG or PEG + CIP. P16, Claudin 2, and ZO-1 were not altered; ICAM1 was increased. Discussion: CIP + PEG enhanced survival post-IR more than PEG alone. The Concurrence of brain hemorrhage, C3 increases and p53 activation post-IR suggests their involvement in the IR-induced brain impairment. CIP + PEG effectively mitigated the brain lesions, suggesting effectiveness of CIP + PEG therapy for treating the IR-induced brain hemorrhage by recovering GFAP and platelets and reducing C3 and p53.

Indexed as

CiprofloxacinGranulocyte Colony-Stimulating FactorIntracranial HemorrhagesAnimalsBody WeightBrainClaudin-2Complement C3FemaleGamma RaysIntercellular Adhesion Molecule-1Interleukin-18MiceMice, Inbred StrainsPolyethylene GlycolsRadiation DosageCiprofloxacinClaudin-2Complement C3Granulocyte Colony-Stimulating FactorIcam1 protein, mouseIntercellular Adhesion Molecule-1Interleukin-18pegylated granulocyte colony-stimulating factorPolyethylene GlycolsRecombinant ProteinsTjp1 protein, mouseZonula Occludens-1 ProteinCiprofloxacinG-CSFglial fibrillary acidic proteinhemorrhageICAM1mouseplateletradiation

Identifiers

PMID38162617
PMCPMC10756649
OpenAlexW4389726710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.